Brought to you by 
Takeda, Lilly co-promote Takeda's oral diabetes product in US
Jun 1998
Executive Summary
In a deal aimed at getting its orally-delivered diabetes product to the US market, Takeda Chemicals will co-promote its pioglitazone in the US with Eli Lilly. Lilly will promote the drug in the US for 7 years from launch, after which Takeda will take over all promotional duties, paying Lilly a declining royalty on sales.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing-Licensing
- Product or Technology Swap
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda, Lilly co-promote Takeda's oral diabetes product in US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice